Mapping the biomarker testing landscape to unlock potential for novel therapeutic in Leukemia
impact summary
Identified barriers and recommended solutions to increase biomarker testing, ensuring client has largest population of eligible patients
Client used recommendations to inform commercial strategy including an unbranded pre-launch education campaign
Mapping the biomarker testing landscape to unlock potential for novel therapeutic in Leukemia
“This is fantastic! I think the deck looks great, and I’m really happy with the rich insights that we were able to gather through this project.”
SITUATION
A rising pharmaceutical company is looking to launch its first FDA-approved treatment for Leukemia. However, successful adoption hinges on healthcare provider awareness of a newly identified biomarker—one that plays a critical role in patient outcomes but exists within a highly fragmented clinical landscape. The company faces the challenge of ensuring that HCPs recognize the biomarker’s relevance and integrate it into their clinical decision-making
APPROACH
To give our client better understanding of the current landscape, we implemented moderator-guided quantitative interviews with HCPs. This methodology allowed for raw data collection through a traditional survey, while also enabling us to answer the “why” behind the “what” in the qualitative portion of the interviews
RESULTS
The findings deepened our client’s understanding of biomarker testing practices, identified key barriers, and enabled forecasting of future testing practices once the new treatment enters the market. Ultimately this work played a key role in developing pivotal solutions relating to barriers associated with testing turnaround time
